Active Procollagen III N-Terminal Propeptide (PIIINP) Homo sapiens (Human) Active protein

P3NP; N-Propeptide Of Type III Procollagen; Procollagen III Amino Terminal Propeptide

Add to Cart Distributors
Overview
Properties
  • Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 97%
  • Isoelectric Point4.0
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Procollagen III N-Terminal Propeptide (PIIINP) Packages (Simulation)
  • Active Procollagen III N-Terminal Propeptide (PIIINP) Packages (Simulation)
  • APA573Hu61.png Figure. SDS-PAGE
  • Active Procollagen III N-Terminal Propeptide (PIIINP) Figure. Western Blot
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Usage

Reconstitute in 20mM Tris, 150mM NaCl (PH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Characterization of the specific and sustained GH1 expression induced by rAAV2/1 in normal adult male ratsPubMed: 20204528
  • A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related FibrosisPubMed: 20532833
  • Comparison of Five Liver Fibrosis Indexes with Serum Levels of Laminin and N Terminal Peptide of Procollagen Type III in Chronic Hepatitis PatientsIntechopen: 18785
  • Is there benefit in optimising heart failure treatment in over-80 year-old patients? (HF-80 study): study protocol for a randomized controlled trial.Trials: 1745-6215
  • Aliskiren and Perindopril Reduce the Levels of Transforming Growth Factor-β in Patients With Non-Diabetic Kidney DiseaseNature: 201214
  • Raised circulating tenascin-C in rheumatoid arthritis.PubMed: 23193984
  • Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure.PubMed: 23067911
  • Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B.PubMed: 22734888
  • Effects of coffee consumption in chronic hepatitis C: a randomized controlled trialPubmed: 23238034
  • Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosisPubmed: 23922364
  • Prevalence, etiology and risk factors of pelvic organ prolapse in premenopausal primiparous womenSpringer: Source
  • Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver FibrosisScienceDirect: S0973688314000073
  • Retroperitoneale FibroseSpringer:Source
  • The status of the pelvic floor in young primiparous womenWiley:Source
  • Clinical significance of markers of collagen metabolism in rheumatic mitral valve diseasePubmed:24603967
  • Serum and urinary procollagen III aminoterminal propeptide as a biomarker of obstructive nephropathy in childrenPubmed:24768785
  • Fast food diet with CCl4 micro-dose induced hepatic-fibrosis-a novel animal modelPubmed:24884574
  • DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2Pubmed:24945829
  • Correlation of HBsAg titers with serum fibrotic maker in patients with chronic hepatitis B infection.Pubmed:24974647
  • Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry diseasePubmed:25073565
  • B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related diseasePubmed:25143523
  • Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with HypertensionPubMed: 25747153
  • The Multi-Biomarker Approach for Heart Failure in Patients with HypertensionPubMed: 25984599
  • The Relationship of the Degree of Hepatic Fibrosis with Hyaluronic Acid, Type 4 Collagen, and Procollagen Type 3 N-Terminal Peptide Levels in Patients with Chronic Viral HepatitisOpenview: 8A0B8C97D72C61741371F33508760B75
  • Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol dietdoi:10.1111
  • Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial populationPubmed:26776557
  • Procollagen markers in microdialysate can predict patient outcome after Achilles tendon rupturecontent:2
  • Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathypubmed:27516211
  • Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRRpubmed:28004175
  • Extracellular microRNA signature in chronic kidney disease.pubmed:28077372
  • Renal Denervation Attenuates Multi-Organ Fibrosis and Improves Vascular Remodeling in Rats with Transverse Aortic Constriction Induced Cardiomyopathypubmed:27889753
  • Procollagen C-Proteinase Enhancer 1 (PCPE-1) as a Plasma Marker of Muscleand Liver Fibrosis in Mice.pubmed:27458976
  • 5-methoxytryptophan is a potential marker for post-myocardial infarction heart failure - apreliminary approach to clinical utility.pubmed:27526355
  • Urinary Type III Procollagen Is Associated With Chronic Allograft Dysfunction and Predicts Graft Survival.pubmed:28219585
  • Achilles tendon rupture healing is enhanced by intermittent pneumatic compression upregulating collagen type I synthesispubmed:28668970
  • Association of HIV infection with biomarkers of kidney injury and fibrosis in the Multicenter AIDS Cohort Studypubmed:28054933
  • Profilin‑1 contributes to cardiac injury induced by advanced glycation end‑products in ratspubmed:28901418
  • Relationship of biomarkers of extracellular matrix with myocardial function in Type 2 diabetes mellituspubmed:28685602
  • Left ventricular reverse remodeling is not related to biopsy‑detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR10.1007/s00380-016-0930-y
  • Matrix Degradation in Human Immunodeficiency Virus Type 1–Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study10.1093/cid/cix231
  • 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis.pubmed:28460256
  • Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events.pubmed:29120858
  • Urinary Biomarkers of Kidney Tubular Damage and Risk of Cardiovascular Disease and Mortality in EldersPubmed:29602632
  • The Association of Biomarkers of Inflammation and Extracellular Matrix Degradation With the Risk of Abdominal Aortic Aneurysm: The ARIC Studyarticle:10.1007
  • Circulating matrix metalloproteinases and procollagen propeptides in inguinal herniaPubmed:29484522
  • Assessment of myocardial fibrosis by late gadolinium enhancement imaging and biomarkers of collagen metabolism in chronic rheumatic mitral regurgitation.Pubmed:29443354
  • Association between reverse electrical remodeling and cardiac fibrosis markers in patients with cardiac resynchronization therapyPubmed:29512624
  • N-терминальный пропептид проколлагена III типа в качестве возможного сывороточного маркера фиброза миокарда у больных сахарным диабетом 2 …:
  • Improvement in Hepatic Fibrosis Biomarkers Associated with Chemokine Receptor Inactivation through Mutation or Therapeutic BlockadePubmed: 30239650
  • microRNA-29a inhibits cardiac fibrosis in Sprague-Dawley rats by downregulating the expression of DNMT3A.Pubmed: 30297596
  • Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study designDoi: 10.1016/j.cct.2018.10.012
  • Association of serum levels of fibrosis-related biomarkers with disease activity in patients with IgG4-related diseasePubmed: 30547825
  • Identification and Modulation of Microenvironment is Crucial for Effective MSC Therapy in Acute Lung InjuryPubmed: 30521764
  • Direktor: Prof. Dr. med. Andreas Mügge
  • Low fibrosis biomarker levels predict cardiac resynchronization therapy responsePubmed: 30988339
  • Development and validation of an in vitro 3D model of NASH with severe fibrotic phenotypePubmed: 30972180
  • Gum Acacia mitigates diclofenac nephrotoxicity by targeting monocyte chemoattractant protein-1, complement receptor-1 and pro-apoptotic pathwaysPubmed: 31042592

Recommend products